This is a working overview of DAC, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-20. Anything still debated is marked as such rather than presented as settled.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naturally occurring niobium (41Nb) is composed of one stable isotope (93Nb). The most stable radioisotope is 92Nb with a half-life of 34.7 million years, followed by 94Nb at a half-life of 20,400 years and 91Nb at 680 years. Other radioisotopes that have been synthesized range from 82Nb to 110Nb; these have half-lives that are less than two hours, except 95Nb (34.991 days), 96Nb (23.35 hours) and 90Nb (14.60 hours). The most stable of the meta states is 93mNb with excitation energy 31 keV and a 16.1 year half-life; this is produced in the decay of 93Zr. The primary decay mode before stable 93Nb is electron capture to zirconium isotopes and the primary mode after is beta emission, with delayed neutron emission starting at 104Nb, leading to molybdenum isotopes. Only 95Nb, along with 97Nb (72 minutes) and heavier isotopes (seconds) are fission products in significant quantity, as the other isotopes are shadowed by stable or very long-lived (93) isotopes of the preceding element zirconium from the usual mode of production through beta decay of neutron-rich fission fragments. 95Nb is the decay product of 95Zr (64 days), so disappearance of 95Nb in used nuclear fuel is slower than would be expected from its own 35-day half-life alone.
24 April Astronomers release close-up global images, for the first time, of the Martian moon Deimos that were taken by the Mars Hope orbiter. The first review of issues identified in meta-science of metascience is published, providing an overview of ten "questionable" practices (QMPs) in the field such as "overplaying the role of replication in science" and preregistration potential. A policy study identifies reduction of car travel activity as the most important transportation policy option in reducing GHG emissions to levels comparable to carbon budget levels, with a "decrease car distance driven and car ownership by over 80% as compared to current levels" by 2027 being effective in "edging close to the designated carbon budget" in their case-study of London and electrification being highly insufficient. On 20 April, an international study indicates that the contemporary domestic policy-proposal of a general speed limit on highways in Germany, the only large country in the world without such, for a quick GHG emissions reduction would also be economically beneficial. It points to a climate change mitigation law (KSG) that mandated emission reductions in this sector that was changed in 2023 so as to remove these obligations. 25 April Scientists, based on new evidence, conclude that Rosalind Franklin was a contributor and "equal player" in the discovery process of DNA, rather than otherwise, as may have been presented subsequently after the time of the discovery.
The name Ghana comes from Wagadu, an empire in west Africa from the 3rd to 12th centuries; Wagadu was termed Ghana by Arab traders involved in the trans-Saharan trade. Ghana is thought to originate from the title Kaya Maghan of the rulers of Wagadu, which translates as ruler of gold.
=== Surgery === A minimally invasive surgical therapy called serial ultrasound-guided aspiration can be performed to treat breast mastitis in an outpatient setting, achieving a better cosmetic postoperative recovery. On the other side, nipple pain caused by tongue-tie can seek a surgical therapy called frenotomy on infants. In this surgery, the frenulum under the tongue will be clipped to improve latch and remove the restriction of tongue movement. Hence, breastfeeding efficiency can be improved. However, it may not instantly relieve nipple pain since infants probably have developed uncommon tongue movements.
=== Cleaning === Dust and dirt are removed from herbarium sheets by using a smoke sponge. Conservators gently rub the place where the dirt is and then softly remove any excess with a fine brush. Care must be taken by conservators when dealing with older prepared specimens that may have traces of toxic chemicals. Making use of personal protective equipment by professionals can reduce the risk of exposure or harm due to dangerous materials.
Sources: en.wikipedia.org
=== In humans === By the age of 4, all notochord residue is replaced by a population of chondrocyte-like cells of unclear origin. Persistence of notochordal cells within the vertebra may cause a pathologic condition: persistent notochordal canal. If the notochord and the nasopharynx do not separate properly during embryonic development, a depression (Tornwaldt bursa) or Tornwaldt cyst may form. The cells are the likely precursors to a rare cancer called chordoma.
== History == Scooter's Coffee was founded in 1998 in Bellevue, Nebraska, by Don and Linda Eckles. In November 2023, Joe Thornton was named the new chief executive officer. John Owen, a former executive for McDonald's and Subway, was named chief operating officer in January 2024. Scooter's announced its goal to reach 1,000 stores by the end of 2024 and began rapidly expanding in 2021. Between August 2021 and 2022, its store count increased by 25%. By December 2022, it had 500 stores, and by October 2023, it had established its 700th store. A 750th store opened in December 2023. In June 2024, after opening its 800th store six months behind schedule, Scooter's Coffee retracted its 1,000-store goal by the end of 2024. In February 2024, Scooter's Coffee built its sixth distribution center, a 183,000-square-foot (17,000 m2) facility in Whitestown, Indiana, to support 300 stores across the Midwest United States.
== Ester terminology == IUPAC states normatively that carbamate "esters are often called urethanes or urethans, a usage that is strictly correct only for the ethyl esters." However, as a descriptive matter, the IUPAC recognizes that "An alternative term for the compounds R2NC(=O)OR' (R' not = H), esters of carbamic acids, R2NC(=O)OH, in strict use limited to the ethyl esters, but widely used in the general sense".
2-Oleoylglycerol (2OG) is a monoacylglycerol that is found in biologic tissues. Its synthesis is derived from diacylglycerol precursors. It is metabolized to oleic acid and glycerol primarily by the enzyme monoacylglycerol lipase (MAGL). In 2011, 2OG was found to be an endogenous ligand to GPR119. 2OG has been shown to increase glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) levels following administration to the small intestine. 2OG has also been discovered to potentiate G protein and not β-arrestin signaling via allosteric binding of the 5-HT2A receptor. 2-Arachidonoylglycerol JZL184
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.